Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1991 2
1992 7
1993 9
1994 8
1995 13
1996 13
1997 9
1998 5
1999 8
2000 6
2001 6
2002 6
2003 13
2004 25
2005 22
2006 22
2007 30
2008 19
2009 17
2010 23
2011 19
2012 23
2013 29
2014 29
2015 31
2016 26
2017 64
2018 73
2019 92
2020 81
2021 15
Text availability
Article attribute
Article type
Publication date

Search Results

670 results
Results by year
Filters applied: . Clear all
Page 1
Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
Pardanani A. Pardanani A. Am J Hematol. 2019 Mar;94(3):363-377. doi: 10.1002/ajh.25371. Epub 2019 Jan 2. Am J Hematol. 2019. PMID: 30536695 Free article. Review.
High response rates have been seen with small-molecule inhibitors that target mutant-KIT, including midostaurin (Food and Drug Administration approved) or avapritinib (investigational). ...
High response rates have been seen with small-molecule inhibitors that target mutant-KIT, including midostaurin (Food and Drug Admini …
Acute myeloid leukaemia.
Short NJ, Rytting ME, Cortes JE. Short NJ, et al. Lancet. 2018 Aug 18;392(10147):593-606. doi: 10.1016/S0140-6736(18)31041-9. Epub 2018 Aug 2. Lancet. 2018. PMID: 30078459 Review.
Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR, DeAngelo DJ. Luskin MR, et al. Expert Rev Hematol. 2017 Dec;10(12):1033-1045. doi: 10.1080/17474086.2017.1397510. Epub 2017 Oct 30. Expert Rev Hematol. 2017. PMID: 29069942 Review.
Areas covered: Standard treatment of FLT3-mutant AML and outcomes. Early clinical development of midostaurin including pharmacokinetics and metabolism. The development of midostaurin in FLT3-mutant AML is then outlined including review of the phase I, II, and III tr …
Areas covered: Standard treatment of FLT3-mutant AML and outcomes. Early clinical development of midostaurin including pharmacokineti …
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H. Stone RM, et al. N Engl J Med. 2017 Aug 3;377(5):454-464. doi: 10.1056/NEJMoa1614359. Epub 2017 Jun 23. N Engl J Med. 2017. PMID: 28644114 Free PMC article. Clinical Trial.
Patients were randomly assigned to receive standard chemotherapy (induction therapy with daunorubicin and cytarabine and consolidation therapy with high-dose cytarabine) plus either midostaurin or placebo; those who were in remission after consolidation therapy entered a m …
Patients were randomly assigned to receive standard chemotherapy (induction therapy with daunorubicin and cytarabine and consolidation thera …
How I treat acute myeloid leukemia in the era of new drugs.
DiNardo CD, Wei AH. DiNardo CD, et al. Blood. 2020 Jan 9;135(2):85-96. doi: 10.1182/blood.2019001239. Blood. 2020. PMID: 31765470
New targeted drugs have emerged, including venetoclax to target B-cell lymphoma 2, midostaurin and gilteritinib to target FLT3, and ivosidenib and enasidenib to target mutant isocitrate dehydrogenase 1 and 2, respectively. ...
New targeted drugs have emerged, including venetoclax to target B-cell lymphoma 2, midostaurin and gilteritinib to target FLT3, and i …
FLT3 inhibitors in acute myeloid leukemia.
Wu M, Li C, Zhu X. Wu M, et al. J Hematol Oncol. 2018 Dec 4;11(1):133. doi: 10.1186/s13045-018-0675-4. J Hematol Oncol. 2018. PMID: 30514344 Free PMC article. Review.
FLT3 inhibitors have been in active clinical development. Midostaurin as the first-in-class FLT3 inhibitor has been approved for treatment of patients with FLT3-mutated AML. In this review, we summarized the preclinical and clinical studies on new FLT3 inhibitors, includin …
FLT3 inhibitors have been in active clinical development. Midostaurin as the first-in-class FLT3 inhibitor has been approved for trea …
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J. Strati P, et al. Am J Hematol. 2015 Apr;90(4):276-81. doi: 10.1002/ajh.23924. Epub 2015 Mar 2. Am J Hematol. 2015. PMID: 25530214 Free PMC article. Clinical Trial.
We investigated the combination of midostaurin and azacitidine (AZA) in patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). Patients received AZA 75 mg m(-2) on days 1-7 and midostaurin 25 mg bid (in cohort 1 of phase I) or 50 mg …
We investigated the combination of midostaurin and azacitidine (AZA) in patients with acute myeloid leukemia (AML) and high risk myel …
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
Antar AI, Otrock ZK, Jabbour E, Mohty M, Bazarbachi A. Antar AI, et al. Leukemia. 2020 Mar;34(3):682-696. doi: 10.1038/s41375-019-0694-3. Epub 2020 Jan 9. Leukemia. 2020. PMID: 31919472 Review.
FLT3 inhibitors are divided into first generation multi-kinase inhibitors (such as sorafenib, lestaurtinib, midostaurin) and next generation inhibitors (such as quizartinib, crenolanib, gilteritinib) based on their potency and specificity of FLT3 inhibition. ...
FLT3 inhibitors are divided into first generation multi-kinase inhibitors (such as sorafenib, lestaurtinib, midostaurin) and next gen …
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer SD, Gilliland DG, Dutreix C, Huntsman-Labed A, Virkus J, Giles FJ. Fischer T, et al. J Clin Oncol. 2010 Oct 1;28(28):4339-45. doi: 10.1200/JCO.2010.28.9678. Epub 2010 Aug 23. J Clin Oncol. 2010. PMID: 20733134 Free PMC article. Clinical Trial.
PURPOSE: Mutations leading to constitutive activation of the FMS-like tyrosine kinase 3 receptor (FLT3) occur in blasts of 30% of patients with acute myeloid leukemia (AML). Midostaurin (PKC412; N-benzoylstaurosporin) is a multitargeted tyrosine kinase inhibitor, wi …
PURPOSE: Mutations leading to constitutive activation of the FMS-like tyrosine kinase 3 receptor (FLT3) occur in blasts of 30% of patients w …
670 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page